OncoMatch/Clinical Trials/NCT06265025
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Is NCT06265025 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including GM103 (Part A) and GM103 (Part B) for head and neck cancer.
Treatment: GM103 (Part A) · GM103 (Part B) · GM103 and Pembrolizumab (Part C) — The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Melanoma
Colorectal Cancer
Renal Cell Carcinoma
Cervical Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Treatment with any systemic anticancer therapies for locally advanced or metastatic within 4 weeks or 6 half-lives of prior anticancer therapy, whichever is shorter, prior to initiation of study treatment
Cannot have received: oncolytic virus (GM103)
Previous treated with GM103 or other oncolytic viruses
Cannot have received: radiation therapy
Radiation therapy within 2 weeks prior to enrollment
Cannot have received: antiviral agent
Use of the antiviral agents within 7 days prior to the first dose of study treatment; or pegylated interferon in the 14 days before the first dose of study treatment
Cannot have received: live vaccine
Patients who have received a live vaccine within 30 days of study enrollment
Cannot have received: investigational drug
Administration of an investigational drug in the 28 days before the first dose of study treatment
Lab requirements
Cardiac function
ejection fraction (ef) > 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify